Hereditary ovarian cancer. Heterogeneity in age at onset
- PMID: 8420679
- DOI: 10.1002/cncr.2820710213
Hereditary ovarian cancer. Heterogeneity in age at onset
Abstract
Background: Hereditary ovarian cancer (HOC) is heterogeneous, with at least three distinctive syndromes, namely, hereditary site-specific ovarian cancer, hereditary breast-ovarian cancer (HBOC) syndrome, and Lynch syndrome II. Ovarian cancer, in accord with virtually all varieties of adult onset cancer, displays an increasing incidence with advancing age; however, it shows an earlier age of onset in hereditary settings.
Methods: Detailed medical and pathology studies were performed on extended ovarian cancer-prone pedigrees, with special attention given to age at ovarian cancer onset.
Results: The age of onset of ovarian cancer is heterogeneous, wherein the average age of onset in HBOC is 52 years, in hereditary site-specific ovarian cancer it is 49 years, and in the Lynch syndrome II it is 45 years, in contrast to its occurrence in the general population, at an average age of 59 years.
Conclusions: These differences are important for the initiation of surveillance and management strategies. Age of onset of ovarian cancer differences in these several hereditary subsets are less striking than they are in the case of other integral forms of cancer in the respective syndromes, such as the breast in the HBOC syndrome. In addition, the phenomenon of extremely early age of onset of ovarian cancer occurs infrequently in HOC when compared to other forms of cancer, such as the breast in HBOC or the colon in Lynch syndrome II. Knowledge about age of onset heterogeneity in HOC may harbor important clues about etiology, pathogenesis, and cancer control.
Similar articles
-
Hereditary ovarian carcinoma.Semin Surg Oncol. 1994 Jul-Aug;10(4):249-54. doi: 10.1002/ssu.2980100404. Semin Surg Oncol. 1994. PMID: 8091066 Review.
-
Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.Oncology. 2015;88(4):226-33. doi: 10.1159/000368836. Epub 2014 Dec 11. Oncology. 2015. PMID: 25503195
-
Hereditary ovarian cancer. Heterogeneity in age at diagnosis.Cancer. 1991 Mar 1;67(5):1460-6. doi: 10.1002/1097-0142(19910301)67:5<1460::aid-cncr2820670534>3.0.co;2-s. Cancer. 1991. PMID: 1991314
-
Hereditary ovarian cancer: a clinicopathological study.Int J Gynecol Pathol. 1992 Jul;11(3):180-7. doi: 10.1097/00004347-199207000-00003. Int J Gynecol Pathol. 1992. PMID: 1399227
-
Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.Surg Pathol Clin. 2016 Jun;9(2):189-99. doi: 10.1016/j.path.2016.01.003. Epub 2016 Apr 11. Surg Pathol Clin. 2016. PMID: 27241103 Review.
Cited by
-
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells.Cancers (Basel). 2019 May 11;11(5):655. doi: 10.3390/cancers11050655. Cancers (Basel). 2019. PMID: 31083587 Free PMC article. Review.
-
Family history in ovarian cancer referral population.J Genet Couns. 1996 Mar;5(1):27-38. doi: 10.1007/BF01408663. J Genet Couns. 1996. PMID: 24234560
-
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.BMC Cancer. 2005 Oct 17;5:134. doi: 10.1186/1471-2407-5-134. BMC Cancer. 2005. PMID: 16229746 Free PMC article.
-
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.BMC Urol. 2022 Nov 30;22(1):196. doi: 10.1186/s12894-022-01141-1. BMC Urol. 2022. PMID: 36451132 Free PMC article.
-
Cancer incidence in the first-degree relatives of ovarian cancer patients.Br J Cancer. 1996 Jul;74(2):280-4. doi: 10.1038/bjc.1996.352. Br J Cancer. 1996. PMID: 8688336 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical